Efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) > and <= 6 months
ONCOLOGY RESEARCH AND TREATMENT（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要